Scher, Howard

Publications

Sort by

Co-Author Network

selected publications

Author Correction: Tumour lineage shapes BRCA-mediated phenotypes. Nature. 2020 Academic Article GET IT
Toward Standardization of Preanalytical Procedures for Cell-Free DNA Profiling. Clinical chemistry. 2020 Editorial Article GET IT
Times cited: 4
The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression. Cancer cell. 2019 Academic Article GET IT
Times cited: 91
Tumour lineage shapes BRCA-mediated phenotypes. Nature. 2019 Academic Article GET IT
Times cited: 221
Reply to L. Dirix, B. De Laere et al, and A. Sharp et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Comment GET IT
Times cited: 5
Pharmacokinetics and Biodistribution of a [⁸⁹Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients. Molecular pharmaceutics. 2019 Academic Article GET IT
Times cited: 21
Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 2019 Academic Article GET IT
Times cited: 561
Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using ⁸⁹Zr-DFO-MSTP2109A Anti-STEAP1 Antibody. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2019 Academic Article GET IT
Times cited: 32
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 218
Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC). British journal of cancer. 2018 Editorial Article GET IT
Times cited: 4
Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate Cancer. Archives of pathology & laboratory medicine. 2018 Academic Article GET IT
Times cited: 7
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. JAMA oncology. 2018 Academic Article GET IT
Times cited: 142
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. The Journal of clinical investigation. 2018 Academic Article GET IT
Times cited: 110
Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. eLife. 2018 Academic Article GET IT
Times cited: 155
Apalutamide for the treatment of prostate cancer. Expert review of anticancer therapy. 2018 Review GET IT
Times cited: 26
Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer. JAMA oncology. 2018 Academic Article GET IT
Times cited: 162
Reply to C. Ren et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Letter GET IT
Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial. JAMA oncology. 2018 Academic Article GET IT
Times cited: 37
Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nature communications. 2018 Academic Article GET IT
Times cited: 28
Reproducibility and Repeatability of Semiquantitative ¹⁸F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2018 Academic Article GET IT
Times cited: 14
The long tail of oncogenic drivers in prostate cancer. Nature genetics. 2018 Academic Article GET IT
Times cited: 458
A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. Investigational new drugs. 2018 Academic Article GET IT
Times cited: 50
Clinical implications of PTEN loss in prostate cancer. Nature reviews. Urology. 2018 Review GET IT
Times cited: 308
Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. JAMA oncology. 2018 Academic Article GET IT
Times cited: 71
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
Times cited: 6
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 159
Drug development for noncastrate prostate cancer in a changed therapeutic landscape. Nature reviews. Clinical oncology. 2017 Review GET IT
Times cited: 7
Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA. 2017 Academic Article GET IT
Times cited: 289
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 60
Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer. Cancer research. 2017 Academic Article GET IT
Times cited: 94
Maintaining Bone Health During Hormonal Therapy for Prostate Cancer. Annals of internal medicine. 2017 Comment GET IT
Times cited: 2
Periprostatic adipose inflammation is associated with high-grade prostate cancer. Prostate cancer and prostatic diseases. 2017 Academic Article GET IT
Times cited: 54
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European urology. 2017 Conference Paper GET IT
Times cited: 367
Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 70
Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1-Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical Prostatectomy. The Journal of urology. 2017 Academic Article GET IT
Times cited: 31
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. Cancer. 2017 Academic Article GET IT
Times cited: 28
Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 41
Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer. European urology. 2016 Academic Article GET IT
Times cited: 135
Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. Science translational medicine. 2016 Academic Article GET IT
Times cited: 17
A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer. Urology. 2016 Academic Article GET IT
Times cited: 39
Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 99
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. JAMA oncology. 2016 Academic Article GET IT
Times cited: 486
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. Urologic oncology. 2016 Academic Article GET IT
Times cited: 36
Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016 Academic Article GET IT
Times cited: 16
The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 42
Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial. Cancer. 2016 Academic Article GET IT
Times cited: 37
Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. European urology. 2016 Editorial Article GET IT
Times cited: 13
First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016 Academic Article GET IT
Times cited: 92
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. The New England journal of medicine. 2016 Academic Article GET IT
Times cited: 1009
Small Glutamine-Rich Tetratricopeptide Repeat-Containing Protein Alpha (SGTA) Ablation Limits Offspring Viability and Growth in Mice. Scientific reports. 2016 Academic Article GET IT
Times cited: 8
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer. European urology. 2016 Academic Article GET IT
Times cited: 111
Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE(-/-) mice. Scientific reports. 2016 Academic Article GET IT
Times cited: 34
Defining new standards of care for men with prostate cancer. Lancet (London, England). 2016 Comment GET IT
Times cited: 2
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. European urology. 2016 Academic Article GET IT
Times cited: 34
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Conference Paper GET IT
Times cited: 881
Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 15
Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients. Cancer journal (Sudbury, Mass.). 2016 Academic Article GET IT
Times cited: 48
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Academic Article GET IT
Times cited: 130
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 101
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 1340
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Academic Article GET IT
Times cited: 37
Reply to A. Addeo and A. Bahl. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Letter GET IT
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. European urology. 2015 Academic Article GET IT
Times cited: 22
Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model. PloS one. 2015 Review GET IT
Times cited: 163
Integrative Clinical Genomics of Advanced Prostate Cancer. Cell. 2015 Article GET IT
Times cited: 340
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications. Cancer. 2015 Academic Article GET IT
Times cited: 24
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 148
An analysis of the association between prostate cancer risk loci, PSA levels, disease aggressiveness and disease-specific mortality. British journal of cancer. 2015 Academic Article GET IT
Times cited: 12
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Conference Paper GET IT
Times cited: 257
Integrative clinical genomics of advanced prostate cancer. Cell. 2015 Academic Article GET IT
Times cited: 2094
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. European urology. 2015 Academic Article GET IT
Times cited: 50
Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI research. 2015 Academic Article GET IT
Times cited: 111
A window into new drug development for urologic oncology. Part II: Bench-to-bedside research improves survival in urologic cancer, and the discovery of better biomarkers can help predict patient response, toxicity, and resistance to therapy. Urologic oncology. 2015 Editorial Article GET IT
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 310
Enzalutamide: Development from bench to bedside. Urologic oncology. 2015 Review GET IT
Times cited: 30
Biomarker development in the context of urologic cancers. Urologic oncology. 2015 Review GET IT
Times cited: 18
Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer. European urology. 2015 Academic Article GET IT
Times cited: 37
Response. Radiology. 2015 Letter GET IT
Times cited: 4
Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 110
A window into new drug development for urologic oncology. Part I: How bench-to-bedside research can result in approval. Urologic oncology. 2015 Editorial Article GET IT
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 50
Observed Advantages of the STAMPEDE Study Design. European urology. 2014 Editorial Article GET IT
Times cited: 4
Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. Cancer cell. 2014 Academic Article GET IT
Times cited: 185
Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians. 2014 GET IT
Times cited: 24
Enzalutamide in European and North American men participating in the AFFIRM trial. BJU international. 2014 Academic Article GET IT
Times cited: 11
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 108
Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014 Academic Article GET IT
Times cited: 983
Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial. European urology. 2014 Academic Article GET IT
Times cited: 31
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. European journal of nuclear medicine and molecular imaging. 2014 Academic Article GET IT
Times cited: 112
Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. The Lancet. Oncology. 2014 Academic Article GET IT
Times cited: 165
Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer. Oncology (Williston Park, N.Y.). 2014 Review GET IT
Times cited: 19
Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer. Molecular & cellular proteomics : MCP. 2014 Academic Article GET IT
Times cited: 25
Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301. European urology. 2014 Academic Article GET IT
Times cited: 42
Enzalutamide in metastatic prostate cancer before chemotherapy. The New England journal of medicine. 2014 Academic Article GET IT
Times cited: 1825
High-risk prostate cancer-classification and therapy. Nature reviews. Clinical oncology. 2014 Review GET IT
Times cited: 273
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. The Lancet. Oncology. 2014 Academic Article GET IT
Times cited: 1115
Androgen dynamics and serum PSA in patients treated with abiraterone acetate. Prostate cancer and prostatic diseases. 2014 Academic Article GET IT
Times cited: 31
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). European urology. 2014 Academic Article GET IT
Times cited: 240
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. European urology. 2014 Academic Article GET IT
Times cited: 34
Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Academic Article GET IT
Times cited: 90
Building on Prostate Cancer Working Group 2 to change the paradigm from palliation to cure. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2014 Review GET IT
Times cited: 3
Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology. 2013 Academic Article GET IT
Times cited: 78
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. British journal of cancer. 2013 Academic Article GET IT
Times cited: 73
Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate cancer and prostatic diseases. 2013 Academic Article GET IT
Times cited: 73
Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 57
Considerations for the successful co-development of targeted cancer therapies and companion diagnostics. Nature reviews. Drug discovery. 2013 Review GET IT
Times cited: 56
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 203
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. European journal of cancer (Oxford, England : 1990). 2013 Academic Article GET IT
Times cited: 72
Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival. European urology. 2013 Academic Article GET IT
Times cited: 58
A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer. Cancer chemotherapy and pharmacology. 2013 Academic Article GET IT
Times cited: 71
Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 106
ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nature medicine. 2013 Academic Article GET IT
Times cited: 220
Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure. Journal of oncology practice. 2013 Academic Article GET IT
Times cited: 24
Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer. Cancer. 2013 Academic Article GET IT
Times cited: 21
Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 104
Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable?. Seminars in oncology. 2013 Review GET IT
Times cited: 32
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 321
Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. European urology. 2013 Review GET IT
Times cited: 113
Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer. European journal of nuclear medicine and molecular imaging. 2013 Academic Article GET IT
Times cited: 144
Factors associated with reduction in use of neoadjuvant androgen suppression therapy before radical prostatectomy. Urology. 2013 Academic Article GET IT
Times cited: 5
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Academic Article GET IT
Times cited: 446
Validation and clinical utility of prostate cancer biomarkers. Nature reviews. Clinical oncology. 2013 Review GET IT
Times cited: 69
β4 Integrin signaling induces expansion of prostate tumor progenitors. The Journal of clinical investigation. 2013 Academic Article GET IT
Times cited: 69
Androgen receptor antagonists in castration-resistant prostate cancer. Cancer journal (Sudbury, Mass.). 2013 Review GET IT
Times cited: 103
Enzalutamide in prostate cancer after chemotherapy. The New England journal of medicine. 2012 Letter GET IT
Times cited: 3
A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine. 2012 Academic Article GET IT
Times cited: 57
Abiraterone in metastatic prostate cancer without previous chemotherapy. The New England journal of medicine. 2012 Academic Article GET IT
Times cited: 2190
Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Academic Article GET IT
Times cited: 78
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. The Lancet. Oncology. 2012 Academic Article GET IT
Times cited: 240
Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses. Clinical chemistry and laboratory medicine. 2012 Academic Article GET IT
Times cited: 8
A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. The Lancet. Oncology. 2012 Academic Article GET IT
Times cited: 94
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. The Lancet. Oncology. 2012 Academic Article GET IT
Times cited: 91
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet. Oncology. 2012 Academic Article GET IT
Times cited: 1120
Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer research. 2012 Academic Article GET IT
Times cited: 163
Reproducibility and clinical correlations of post-treatment changes on CT of prostate cancer bone metastases treated with chemotherapy. The British journal of radiology. 2012 Academic Article GET IT
Times cited: 5
Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England journal of medicine. 2012 Academic Article GET IT
Times cited: 3504
Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building. Journal of pharmacokinetics and pharmacodynamics. 2012 Academic Article GET IT
Times cited: 11
Considerations in the development of circulating tumor cell technology for clinical use. Journal of translational medicine. 2012 Review GET IT
Times cited: 278
Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer. Current treatment options in oncology. 2012 Review GET IT
Times cited: 27
Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 91
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Academic Article GET IT
Times cited: 29
Computer-aided quantitative bone scan assessment of prostate cancer treatment response. Nuclear medicine communications. 2012 Academic Article GET IT
Times cited: 40
Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors. Cancer chemotherapy and pharmacology. 2012 Academic Article GET IT
Times cited: 2
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. European urology. 2012 Academic Article GET IT
Times cited: 141
A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. International journal of cancer. 2012 Academic Article GET IT
Times cited: 29
ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer research. 2012 Academic Article GET IT
Times cited: 528
Prostate cancer in 2011: Hitting old targets better and identifying new targets. Nature reviews. Clinical oncology. 2012 Review GET IT
Times cited: 12
Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Academic Article GET IT
Times cited: 136
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer chemotherapy and pharmacology. 2011 Academic Article GET IT
Times cited: 28
Locally advanced prostate cancer: a population-based study of treatment patterns. BJU international. 2011 Academic Article GET IT
Times cited: 41
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. European urology. 2011 Review GET IT
Times cited: 147
Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 46
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. Cancer chemotherapy and pharmacology. 2011 Academic Article GET IT
Times cited: 21
Febrile neutropenia and infection in the ASCENT studies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Letter GET IT
Times cited: 2
Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2011 Academic Article GET IT
Times cited: 39
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Review GET IT
Times cited: 187
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. European urology. 2011 Academic Article GET IT
Times cited: 170
Circulating tumor cells as biomarkers in prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Review GET IT
Times cited: 202
Developing imaging strategies for castration resistant prostate cancer. Acta oncologica (Stockholm, Sweden). 2011 Academic Article GET IT
Times cited: 39
Abiraterone and increased survival in metastatic prostate cancer. The New England journal of medicine. 2011 Academic Article GET IT
Times cited: 3473
Circulating cancer cells and their clinical applications. Clinical chemistry. 2011 Academic Article GET IT
Times cited: 11
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer cell. 2011 Academic Article GET IT
Times cited: 917
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 201
Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signalling. Nature communications. 2011 Academic Article GET IT
Circulating tumors cells as biomarkers: progress toward biomarker qualification. Cancer journal (Sudbury, Mass.). 2011 Review GET IT
Times cited: 71
Using confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory (BPI). Journal of pain and symptom management. 2010 Academic Article GET IT
Times cited: 155
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 38
Prostate cancer topography and patterns of lymph node metastasis. The American journal of surgical pathology. 2010 Academic Article GET IT
Times cited: 37
Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer. 2010 Academic Article GET IT
Times cited: 57
Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 104
Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 388
Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2010 Academic Article GET IT
Times cited: 129
Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer. PloS one. 2010 Academic Article GET IT
Times cited: 13
Detection of androgen receptor mutations in circulating tumor cells: highlights of the long road to clinical qualification. Clinical chemistry. 2010 Editorial Article GET IT
Times cited: 5
Integrative genomic profiling of human prostate cancer. Cancer cell. 2010 Academic Article GET IT
Times cited: 2799
Susceptibility loci associated with prostate cancer progression and mortality. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 73
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (London, England). 2010 Academic Article GET IT
Times cited: 924
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer chemotherapy and pharmacology. 2010 Academic Article GET IT
Times cited: 100
Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 222
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 379
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 362
A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. The Journal of clinical investigation. 2010 Academic Article GET IT
Times cited: 266
Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2010 Academic Article GET IT
Times cited: 100
The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations. Pain medicine (Malden, Mass.). 2010 Academic Article GET IT
Times cited: 127
Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer. 2009 Academic Article GET IT
Times cited: 117
Finding the place of histone deacetylase inhibitors in prostate cancer therapy. Expert review of clinical pharmacology. 2009 Academic Article GET IT
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. The Lancet. Oncology. 2009 Academic Article GET IT
Times cited: 265
Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer. Clinical genitourinary cancer. 2009 Academic Article GET IT
Times cited: 25
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Review GET IT
Times cited: 253
NF-kappaB regulates androgen receptor expression and prostate cancer growth. The American journal of pathology. 2009 Academic Article GET IT
Times cited: 154
Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. BJU international. 2009 Academic Article GET IT
Times cited: 60
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 80
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (New York, N.Y.). 2009 Academic Article GET IT
Times cited: 1755
Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. European urology. 2009 Academic Article GET IT
Times cited: 71
A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin. Endocrinology. 2009 Academic Article GET IT
Times cited: 25
Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 176
Bone marrow aspiration for disseminated tumor cell detection: a must-have test or is the jury still out?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Editorial Article GET IT
Times cited: 16
Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival. Clinical chemistry. 2009 Academic Article GET IT
Times cited: 117
Quantitative analysis of circulating tumor cells as a survival predictor in metastatic castration-resistant prostate cancer: missing parts in a superb study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Letter GET IT
Times cited: 1
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. The Lancet. Oncology. 2009 Academic Article GET IT
Times cited: 518
TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer research. 2009 Academic Article GET IT
Times cited: 221
Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy. International journal of cancer. 2009 Academic Article GET IT
Times cited: 17
Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer research. 2009 Academic Article GET IT
Times cited: 149
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clinical genitourinary cancer. 2009 Academic Article GET IT
Times cited: 20
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). Journal of neuro-oncology. 2008 Academic Article GET IT
Times cited: 152
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 1810
Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel. Cancer. 2008 Academic Article GET IT
Times cited: 18
Targeting the androgen receptor pathway in prostate cancer. Current opinion in pharmacology. 2008 Review GET IT
Times cited: 336
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 23
Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2008 Academic Article GET IT
Times cited: 67
Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 125
Expression of prostate-specific membrane antigen in renal cortical tumors. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2008 Academic Article GET IT
Times cited: 32
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. 2008 GET IT
Times cited: 1830
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 559
Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 148
A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer. The Journal of urology. 2007 Academic Article GET IT
Times cited: 36
Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha. Cancer research. 2007 Academic Article GET IT
Times cited: 79
American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Review GET IT
Times cited: 79
A polyvalent vaccine for high-risk prostate patients: "are more antigens better?". Cancer immunology, immunotherapy : CII. 2007 Academic Article GET IT
Times cited: 65
Improved prediction of prostate cancer recurrence through systems pathology. The Journal of clinical investigation. 2007 Academic Article GET IT
Times cited: 101
Identification of novel androgen receptor target genes in prostate cancer. Molecular cancer. 2007 Academic Article GET IT
Times cited: 75
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 71
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. 2007 GET IT
Times cited: 465
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 304
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 13
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 189
The association between measures of progression and survival in castrate-metastatic prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 66
Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities. Journal of the American Medical Informatics Association : JAMIA. 2007 Academic Article GET IT
Times cited: 95
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 89
Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Review GET IT
Times cited: 49
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Molecular cancer therapeutics. 2007 Academic Article GET IT
Times cited: 91
Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy data. Medical decision making : an international journal of the Society for Medical Decision Making. 2007 Academic Article GET IT
Times cited: 3
Rapid androgen cycling as treatment for patients with prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 22
Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nature clinical practice. Oncology. 2006 Review GET IT
Times cited: 53
Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. The Lancet. Oncology. 2006 Academic Article GET IT
Times cited: 447
The natural history of noncastrate metastatic prostate cancer after radical prostatectomy. European urology. 2006 Academic Article GET IT
Times cited: 48
Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 66
Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression. Urology. 2006 Academic Article GET IT
Times cited: 52
An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib. 2006 GET IT
Times cited: 30
ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression. Oncogene. 2006 Academic Article GET IT
Times cited: 86
Assessing anxiety in men with prostate cancer: further data on the reliability and validity of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC). Psychosomatics. 2006 Academic Article GET IT
Times cited: 111
Differential exoprotease activities confer tumor-specific serum peptidome patterns. The Journal of clinical investigation. 2006 Academic Article GET IT
Times cited: 684
Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 80
Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma. Cancer. 2005 Academic Article GET IT
Times cited: 47
The progress and promise of molecular imaging probes in oncologic drug development. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Review GET IT
Times cited: 214
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Review GET IT
Times cited: 878
Critical function for ADAM9 in mouse prostate cancer. Cancer research. 2005 Academic Article GET IT
Times cited: 95
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 110
Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 93
Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. International journal of cancer. 2005 Academic Article GET IT
Times cited: 50
Second-line chemotherapy for prostate cancer: patient characteristics and survival. Clinical prostate cancer. 2005 Academic Article GET IT
Times cited: 32
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 2005 Academic Article GET IT
Times cited: 1578
Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 15
Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Review GET IT
Times cited: 116
2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 179
Bladder cancer "adjuvant-lite": tastes great (works as well) and less filling (less toxic)?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Editorial Article GET IT
Times cited: 5
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 821
A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21. Vaccine. 2005 Academic Article GET IT
Times cited: 74
Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen. Urology. 2005 Academic Article GET IT
Times cited: 7
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 105
Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer. Current urology reports. 2005 Review GET IT
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Review GET IT
Times cited: 546
Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 148
Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 179
Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 119
Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer. Applied immunohistochemistry & molecular morphology : AIMM. 2005 Academic Article GET IT
Times cited: 23
Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Cancer immunology, immunotherapy : CII. 2005 Academic Article GET IT
Times cited: 112
Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 98
Evidence for a p27 tumor suppressive function independent of its role regulating cell proliferation in the prostate. Proceedings of the National Academy of Sciences of the United States of America. 2004 Academic Article GET IT
Times cited: 37
Imaging therapeutic response in human bone marrow using rapid whole-body MRI. Magnetic resonance in medicine. 2004 Academic Article GET IT
Times cited: 63
Current management of hormone-refractory prostate cancer. Clinical advances in hematology & oncology : H&O. 2004 Academic Article GET IT
Times cited: 1
Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events. Molecular carcinogenesis. 2004 Academic Article GET IT
Times cited: 39
PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2004 Academic Article GET IT
Times cited: 76
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocrine-related cancer. 2004 Review GET IT
Times cited: 205
Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Molecular cancer therapeutics. 2004 Academic Article GET IT
Times cited: 69
Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer. Urology. 2004 Academic Article GET IT
Times cited: 23
American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. 2004 GET IT
Times cited: 179
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. Cancer. 2004 Academic Article GET IT
Times cited: 31
Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer. Current oncology reports. 2004 Review GET IT
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine. 2004 Academic Article GET IT
Times cited: 114
Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology. 2004 Academic Article GET IT
Times cited: 251
Decreased retinoid X receptor-alpha protein expression in basal cells occurs in the early stage of human prostate cancer development. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2004 Academic Article GET IT
Times cited: 20
Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2004 Academic Article GET IT
Times cited: 292
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. 2004 GET IT
Times cited: 178
Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. The Journal of urology. 2004 Academic Article GET IT
Times cited: 83
Chemotherapeutic response with single agent gemcitabine in metastatic Bellini duct tumor. Cancer investigation. 2004 Letter GET IT
Effective antigen cross-presentation by prostate cancer patients' dendritic cells: implications for prostate cancer immunotherapy. Prostate cancer and prostatic diseases. 2004 Academic Article GET IT
Times cited: 13
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. The American journal of pathology. 2004 Academic Article GET IT
Times cited: 486
Glutathione S-transferase P1 Ile105Val polymorphism, cigarette smoking and prostate cancer. Cancer detection and prevention. 2004 Academic Article GET IT
Times cited: 34
Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids. Cancer research. 2003 Academic Article GET IT
Times cited: 62
Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 166
Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. Cancer. 2003 Academic Article GET IT
Times cited: 34
Advances in imaging in the postoperative patient with a rising prostate-specific antigen level. Seminars in oncology. 2003 Review GET IT
Times cited: 69
DNA vaccines: an active immunization strategy for prostate cancer. Seminars in oncology. 2003 Review GET IT
Times cited: 50
Hsp90 as a therapeutic target in prostate cancer. Seminars in oncology. 2003 Review GET IT
Times cited: 141
Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Annals of oncology : official journal of the European Society for Medical Oncology. 2003 Academic Article GET IT
Times cited: 63
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 648
Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer research. 2003 Academic Article GET IT
Times cited: 216
Prostate cancer: a dynamic illness with shifting targets. The Lancet. Oncology. 2003 Review GET IT
Times cited: 41
Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer Center. Critical reviews in oncology/hematology. 2003 Review GET IT
Times cited: 5
Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 15
The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with with prostate cancer. Cancer. 2003 Academic Article GET IT
Times cited: 187
Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer research. 2003 Academic Article GET IT
Times cited: 281
Prostate carcinoma: defining therapeutic objectives and improving overall outcomes. Cancer. 2003 Review GET IT
Times cited: 42
p27 as a target for cancer therapeutics. Cancer cell. 2003 Review GET IT
Times cited: 139
Clinical approaches to osseous metastases in prostate cancer. The oncologist. 2003 Review GET IT
Times cited: 27
Estimating survival benefit in castrate metastatic prostate cancer: decision making in proceeding to a definitive phase III trial. Urology. 2003 Academic Article GET IT
Times cited: 7
Editorial: States and state transitions are all that really matter. The Journal of urology. 2002 Editorial Article GET IT
Times cited: 3
Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine. Urology. 2002 Review GET IT
Times cited: 13
Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 97
Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 106
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 353
Prostate-specific antigen as a marker of disease activity in prostate cancer. Oncology (Williston Park, N.Y.). 2002 Review GET IT
Times cited: 25
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proceedings of the National Academy of Sciences of the United States of America. 2002 Academic Article GET IT
Times cited: 468
Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer research. 2002 Academic Article GET IT
Times cited: 426
Prostate-specific antigen as a marker of disease activity in prostate cancer. Oncology (Williston Park, N.Y.). 2002 Review GET IT
Times cited: 31
Quantifying the amount of variation in survival explained by prostate-specific antigen. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 29
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer cell. 2002 Comment GET IT
Times cited: 767
Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 61
Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology. 2002 Academic Article GET IT
Times cited: 180
Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies. Surgical oncology. 2002 Review GET IT
Times cited: 14
Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of (18)F-FDG PET. The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR). 2002 Academic Article GET IT
Times cited: 20
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 435
Outcome predictions for patients with metastatic prostate cancer. Seminars in urologic oncology. 2002 Academic Article GET IT
Times cited: 16
Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 178
HER-2 profiling and targeting in prostate carcinoma. Cancer. 2002 Academic Article GET IT
Times cited: 125
Picking the winners in a sea of plenty. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 23
Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2002 Academic Article GET IT
Times cited: 167
Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements. Acta oncologica (Stockholm, Sweden). 2002 Academic Article GET IT
Times cited: 36
HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001 Academic Article GET IT
Times cited: 143
Local detection of prostate cancer by positron emission tomography with 2-fluorodeoxyglucose: comparison of filtered back projection and iterative reconstruction with segmented attenuation correction. The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR). 2001 Academic Article GET IT
Times cited: 21
Inverse associations between plasma lycopene and other carotenoids and prostate cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2001 Academic Article GET IT
Times cited: 151
Collocation of androgen receptor gene mutations in prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001 Academic Article GET IT
Times cited: 165
Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001 Academic Article GET IT
Times cited: 125
The Collection of Indirect and Nonmedical Direct Costs (COIN) form: a new tool for collecting the invisible costs of androgen independent prostate carcinoma. Cancer. 2001 Academic Article GET IT
Times cited: 31
Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer. Prostate cancer and prostatic diseases. 2001 Academic Article GET IT
Times cited: 27
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 187
HER2 in prostate cancer--a viable target or innocent bystander?. Journal of the National Cancer Institute. 2000 Editorial Article GET IT
Times cited: 36
A potential role for activated HER-2 in prostate cancer. Seminars in oncology. 2000 Review GET IT
Times cited: 40
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000 Academic Article GET IT
Times cited: 781
Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer research. 2000 Academic Article GET IT
Times cited: 144
Novel strategies and therapeutics for the treatment of prostate carcinoma. Cancer. 2000 Review GET IT
Times cited: 46
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer research. 2000 Academic Article GET IT
Times cited: 589
Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000 Academic Article GET IT
Times cited: 31
The phase II/III transition. Toward the proof of efficacy in cancer clinical trials. Controlled clinical trials. 2000 Academic Article GET IT
Times cited: 46
Identification and characterization of circulating prostate carcinoma cells. Cancer. 2000 Academic Article GET IT
Times cited: 75
Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. Cancer research. 2000 Academic Article GET IT
Times cited: 60
Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000 Academic Article GET IT
Times cited: 192
Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Times cited: 57
Expression of c-kit and kit-ligand in benign and malignant prostatic tissues. Histology and histopathology. 2000 Academic Article GET IT
Times cited: 52
Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer. 2000 Academic Article GET IT
Times cited: 111
Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens. Proceedings of the National Academy of Sciences of the United States of America. 2000 Academic Article GET IT
Times cited: 58
Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology. 2000 Academic Article GET IT
Times cited: 200
The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000 Academic Article GET IT
Times cited: 48
A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility. Cancer chemotherapy and pharmacology. 2000 Academic Article GET IT
Times cited: 17
Evaluation of drug delivery and survival impact of dose-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancer. Cancer investigation. 2000 Academic Article GET IT
Times cited: 9
Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. Journal of the National Cancer Institute. 1999 Academic Article GET IT
Times cited: 220
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Academic Article GET IT
Times cited: 920
Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Academic Article GET IT
Times cited: 612
Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer research. 1999 Academic Article GET IT
Times cited: 139
Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clinical cancer research : an official journal of the American Association for Cancer Research. 1999 Academic Article GET IT
Times cited: 129
Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Academic Article GET IT
Times cited: 149
Peptide and carbohydrate vaccines in relapsed prostate cancer: immunogenicity of synthetic vaccines in man--clinical trials at Memorial Sloan-Kettering Cancer Center. Seminars in oncology. 1999 Review GET IT
Times cited: 37
Rising PSAs after primary therapy: active or passive intervention. Seminars in urologic oncology. 1999 Review GET IT
Times cited: 5
Editorial. Prostate cancer and prostatic diseases. 1999 Academic Article GET IT
Detection of prostatic specific membrane antigen messenger RNA using immunobead reverse transcriptase polymerase chain reaction. Diagnostic molecular pathology : the American journal of surgical pathology, part B. 1999 Academic Article GET IT
Times cited: 33
Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 1999 Academic Article GET IT
Times cited: 42
Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proceedings of the National Academy of Sciences of the United States of America. 1999 Academic Article GET IT
Times cited: 251
Management of prostate cancer after prostatectomy: treating the patient, not the PSA. JAMA. 1999 Editorial Article GET IT
Times cited: 19
Differential Metabolism and Pharmacokinetics of L-[1-(11)C]-Methionine and 2-[(18)F] Fluoro-2-deoxy-D-glucose (FDG) in Androgen Independent Prostate Cancer. Clinical positron imaging : official journal of the Institute for Clinical P.E.T. 1999 Academic Article GET IT
Times cited: 48
Editorial. Prostate cancer and prostatic diseases. 1999 Academic Article GET IT
Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 1999 Academic Article GET IT
Times cited: 89
Editorial. Prostate cancer and prostatic diseases. 1999 Academic Article GET IT
Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. Cancer. 1999 Academic Article GET IT
Times cited: 9
Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Academic Article GET IT
Times cited: 203
A Fully Synthetic Globo H Carbohydrate Vaccine Induces a Focused Humoral Response in Prostate Cancer Patients: A Proof of Principle. Angewandte Chemie (International ed. in English). 1999 Academic Article GET IT
Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. Journal of the National Cancer Institute. 1999 Academic Article GET IT
Times cited: 159
Can p53 help select patients with invasive bladder cancer for bladder preservation?. The Journal of urology. 1999 Academic Article GET IT
Times cited: 46
The microtubule-stabilizing agents epothilones A and B and their desoxy-derivatives induce mitotic arrest and apoptosis in human prostate cancer cells. Prostate cancer and prostatic diseases. 1999 Academic Article GET IT
Editorial. Prostate cancer and prostatic diseases. 1998 Academic Article GET IT
An open letter to the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
Times cited: 1
Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. Journal of the National Cancer Institute. 1998 Academic Article GET IT
Times cited: 245
Small cell and anaplastic prostate cancer: correlation between CT findings and prostate-specific antigen level. Radiology. 1998 Academic Article GET IT
Times cited: 30
[Recommendations for the diagnosis, treatment, and follow-up of cancer of the bladder]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 1998 Academic Article GET IT
Times cited: 1
Detectable tumor cells in the blood and bone marrow: smoke or fire?. Cancer. 1998 Editorial Article GET IT
Times cited: 15
Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
Times cited: 83
Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer research. 1998 Academic Article GET IT
Times cited: 61
A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clinical cancer research : an official journal of the American Association for Cancer Research. 1998 Academic Article GET IT
Times cited: 201
Interstitial pneumonitis following bicalutamide treatment for prostate cancer. 1998 GET IT
Times cited: 19
NCCN urothelial cancer practice guidelines. National Comprehensive Cancer Network. 1998 GET IT
Times cited: 48
Workgroup 3: transgenic and reconstitution models of prostate cancer. The Prostate. 1998 Conference Paper GET IT
Times cited: 47
Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. Cancer. 1998 Academic Article GET IT
Times cited: 827
Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
Times cited: 170
Uroplakin II gene is expressed in transitional cell carcinoma but not in bilharzial bladder squamous cell carcinoma: alternative pathways of bladder epithelial differentiation and tumor formation. Cancer research. 1998 Academic Article GET IT
Times cited: 85
Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 1998 Academic Article GET IT
Times cited: 71
Unravelling the confusions in prostatic disease. Prostate cancer and prostatic diseases. 1998 Academic Article GET IT
Expression of granulocyte-macrophage colony-stimulating factor receptors in human prostate cancer. Blood. 1998 Academic Article GET IT
Times cited: 40
Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 1998 Academic Article GET IT
Times cited: 181
Immunological approaches for the treatment of prostate cancer. Seminars in urologic oncology. 1998 Review GET IT
Times cited: 30
Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nature medicine. 1998 Academic Article GET IT
Times cited: 245
Reversal of the low-affinity neurotrophin receptor stromal-epithelial expression pattern between benign and malignant human prostate. Urologic oncology. 1998 Academic Article GET IT
Times cited: 1
Sertraline relieves hot flashes secondary to medical castration as treatment of advanced prostate cancer. 1998 GET IT
Times cited: 57
Editorial. Prostate cancer and prostatic diseases. 1997 Academic Article GET IT
Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue. The Prostate. 1997 Academic Article GET IT
Times cited: 85
Expression of cyclin D1, but not cyclins E and A, is related to progression in bilharzial bladder cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 1997 Academic Article GET IT
Times cited: 19
Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon, and sarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 1997 Academic Article GET IT
Times cited: 81
Combined-modality therapy for bladder cancer. Oncology (Williston Park, N.Y.). 1997 Review GET IT
Times cited: 4
Editorial. Prostate cancer and prostatic diseases. 1997 Academic Article GET IT
Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Academic Article GET IT
Times cited: 200
Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. Urology. 1997 Academic Article GET IT
Times cited: 58
Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Academic Article GET IT
Times cited: 47
Chromosome 16 in primary prostate cancer: a microsatellite analysis. International journal of cancer. 1997 Academic Article GET IT
Times cited: 20
Cigarette smoking and chromosome 9 alterations in bladder cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 1997 Academic Article GET IT
Times cited: 18
Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Academic Article GET IT
Times cited: 336
Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. The Urologic clinics of North America. 1997 Academic Article GET IT
Times cited: 62
Alterations affecting the p53 control pathway in bilharzial-related bladder cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 1997 Academic Article GET IT
Times cited: 27
Assessment of hormone refractory prostate cancer. Urology. 1997 Academic Article GET IT
Times cited: 29
'Casodex': defining the role of antiandrogens. The cancer journal from Scientific American. 1997 Comment GET IT
Times cited: 2
Free/total prostate-specific antigen ratio--hope and controversies. European urology. 1997 Review GET IT
Times cited: 12
The antiandrogen withdrawal syndrome in relapsed prostate cancer. European urology. 1997 Academic Article GET IT
Times cited: 28
Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. The Journal of clinical endocrinology and metabolism. 1996 Academic Article GET IT
Times cited: 210
Clinical use of posttherapy prostate-specific antigen changes in advanced prostate cancer. Seminars in oncology. 1996 Review GET IT
Times cited: 4
Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach. Seminars in oncology. 1996 Review GET IT
Times cited: 21
Clinical trials in relapsed prostate cancer: defining the target. Journal of the National Cancer Institute. 1996 Review GET IT
Times cited: 132
Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy. British journal of cancer. 1996 Academic Article GET IT
Times cited: 49
The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy. 1996 Academic Article GET IT
Times cited: 241
Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer research. 1996 Academic Article GET IT
Times cited: 281
Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nuclear medicine and biology. 1996 Academic Article GET IT
Times cited: 129
Methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and cystectomy for unresectable bladder cancer. The Journal of urology. 1996 Academic Article GET IT
Times cited: 52
Acid phosphatase: defining a role in androgen-independent prostate cancer. Urology. 1996 Academic Article GET IT
Times cited: 15
Genistein is a natural inhibitor of hexose and dehydroascorbic acid transport through the glucose transporter, GLUT1. The Journal of biological chemistry. 1996 Academic Article GET IT
Times cited: 111
Telomerase activity is repressed during differentiation of maturation-sensitive but not resistant human tumor cell lines. Cancer research. 1996 Academic Article GET IT
Times cited: 122
Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. Urology. 1996 Review GET IT
Times cited: 68
Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument for. European urology. 1996 Review GET IT
Times cited: 2
A pharmacogically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer. The Journal of urology. 1995 Academic Article GET IT
Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Advanced bladder cancer overview collaboration. The Journal of urology. 1995 Academic Article GET IT
Times cited: 5
Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. The Journal of urology. 1995 Academic Article GET IT
Times cited: 1
Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 96
Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 29
Hormone-refractory (D3) prostate cancer: refining the concept. Urology. 1995 Review GET IT
Times cited: 185
Primary squamous cell carcinoma of the prostate after radiation seed implantation for adenocarcinoma. 1995 GET IT
Times cited: 25
Neoadjuvant and adjuvant chemotherapy in advanced disease--what are the effects on survival and prognosis?. International journal of urology : official journal of the Japanese Urological Association. 1995 Review GET IT
Times cited: 33
Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 239
Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clinical cancer research : an official journal of the American Association for Cancer Research. 1995 Academic Article GET IT
Times cited: 211
Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 197
Prostate cancer in the era of prostate-specific antigen. Current opinion in oncology. 1995 Review GET IT
Times cited: 16
Distinguishing prognostic and treatment-predictive information for localized prostate cancer. Urology. 1995 Academic Article GET IT
Times cited: 6
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5 year follow-up. The Journal of urology. 1995 Academic Article GET IT
Intracavitary birdcage resonator: applications to the human prostate. Journal of magnetic resonance imaging : JMRI. 1995 Academic Article GET IT
Prognostic factors in bladder cancer after primary M-VAC. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995 Letter GET IT
Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues. The Journal of urology. 1994 Academic Article GET IT
Times cited: 85
An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma. The Journal of urology. 1994 Academic Article GET IT
P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. Annals of oncology : official journal of the European Society for Medical Oncology. 1994 Academic Article GET IT
Times cited: 48
Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994 Academic Article GET IT
Times cited: 186
Bone metastases: improving the therapeutic index. Seminars in oncology. 1994 Review GET IT
Times cited: 89
Introduction: prostate cancer. Seminars in oncology. 1994 Academic Article GET IT
Times cited: 1
Prostate cancer: improving the therapeutic index. Seminars in oncology. 1994 Review GET IT
Times cited: 4
A bladder cancer multi-institutional experience with total cystectomy for muscle-invasive bladder cancer. The Journal of urology. 1994 Academic Article GET IT
High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder. The Journal of urology. 1994 Academic Article GET IT
Times cited: 7
Post-therapy change in prostate-specific antigen levels as a clinical trial endpoint in hormone-refractory prostatic cancer: a trial with 10-ethyl-deaza-aminopterin. Urology. 1994 Academic Article GET IT
Times cited: 8
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994 Academic Article GET IT
Times cited: 141
Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care. Cancer. 1994 Academic Article GET IT
Times cited: 287
Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis. The Journal of urology. 1994 Academic Article GET IT
Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994 Academic Article GET IT
Times cited: 67
Prostate cancer: how can a common disease be so controversial?. Current opinion in oncology. 1994 Review GET IT
Times cited: 9
Elevated plasma lipid peroxide content correlates with rapid plasma clearance of all-trans-retinoic acid in patients with advanced cancer. Cancer research. 1994 Academic Article GET IT
Times cited: 29
Bladder cancer: advances in biology and treatment. Critical reviews in oncology/hematology. 1994 Review GET IT
Times cited: 8
Cisplatin, fluorouracil, and leucovorin. Increased toxicity without improved response in squamous cell head and neck cancer. Archives of otolaryngology--head & neck surgery. 1994 Academic Article GET IT
Times cited: 35
Differences in the pharmacokinetic properties of orally administered all-trans-retinoic acid and 9-cis-retinoic acid in the plasma of nude mice. Drug metabolism and disposition: the biological fate of chemicals. 1994 Academic Article GET IT
Times cited: 57
Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. Cancer. 1993 Academic Article GET IT
Times cited: 19
New approaches to the treatment of bladder cancer. The New England journal of medicine. 1993 Editorial Article GET IT
Times cited: 6
Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993 Academic Article GET IT
Times cited: 376
Incorporating tumor biology into therapy for prostate cancer. Current opinion in oncology. 1993 Review GET IT
Times cited: 2
Suramin: here to stay!?. Journal of the National Cancer Institute. 1993 Editorial Article GET IT
Times cited: 20
Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993 Academic Article GET IT
Times cited: 356
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993 Academic Article GET IT
Times cited: 306
Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993 Academic Article GET IT
Times cited: 100
Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993 Academic Article GET IT
Times cited: 42
Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. 1993 GET IT
Times cited: 327
Treatment of brain metastases from bladder cancer. The Journal of urology. 1993 Academic Article GET IT
Times cited: 31
A phase II trial of deoxyspergualin in recurrent squamous cell head and neck cancer. Investigational new drugs. 1993 Academic Article GET IT
Times cited: 4
Immune-mediated thrombocytopenia secondary to suramin. 1993 GET IT
Times cited: 13
Phase II trial of gallium nitrate in previously treated patients with small cell lung cancer. Investigational new drugs. 1993 Academic Article GET IT
Times cited: 11
Neoadjuvant versus adjuvant chemotherapy in invasive bladder cancer. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 1993 Review GET IT
Times cited: 2
The evolving role of chemotherapy of germ cell tumors. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 1993 Review GET IT
Times cited: 1
Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy. Cancer. 1992 Academic Article GET IT
Times cited: 43
Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. A possible new recombinant granulocyte colony-stimulating factor toxicity. 1992 GET IT
Times cited: 59
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. The Journal of urology. 1992 Academic Article GET IT
Times cited: 6
Spinal epidural tumor in patients with prostate cancer. Clinical and radiographic predictors of response to radiation therapy. Cancer. 1992 Academic Article GET IT
Times cited: 62
Systemic chemotherapy in regionally advanced bladder cancer. Theoretical considerations and results. The Urologic clinics of North America. 1992 Review GET IT
Times cited: 17
Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. Cancer research. 1992 Academic Article GET IT
Times cited: 49
A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1992 Academic Article GET IT
Times cited: 70
Prostatic cancer: are we closer to rational treatment selection?. Current opinion in oncology. 1992 Review GET IT
Times cited: 4
Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. The Journal of urology. 1992 Academic Article GET IT
Times cited: 193
The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer--Genitourinary Group. The Journal of urology. 1992 Academic Article GET IT
Times cited: 126
Chemotherapy for metastatic bladder cancer. Hematology/oncology clinics of North America. 1992 Review GET IT
Times cited: 5
Chemotherapy for muscle-infiltrating bladder cancer. Hematology/oncology clinics of North America. 1992 Review GET IT
Times cited: 10
Therapeutic alternatives for hormone-refractory prostatic cancer. Seminars in urology. 1992 Review GET IT
Times cited: 20
A reappraisal of the role of prophylactic cranial irradiation in limited small cell lung cancer. International journal of radiation oncology, biology, physics. 1992 Academic Article GET IT
Times cited: 34
Chemotherapy for urothelial tract malignancies: breaking the deadlock. Seminars in surgical oncology. 1992 Review GET IT
Times cited: 40
Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors. Advances in experimental medicine and biology. 1992 Review GET IT
Times cited: 1
Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer. Cancer treatment and research. 1992 Academic Article GET IT
Times cited: 10
Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases. Seminars in nuclear medicine. 1992 Review GET IT
Times cited: 106
Suramin as an archetypical compound in the development of growth factor antagonists for inhibition of genitourinary tumors. Cancer treatment and research. 1992 Review GET IT
Times cited: 8
Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. Cancer. 1991 Academic Article GET IT
Times cited: 89
The evolving role of chemotherapy for muscle infiltrating bladder cancer. Seminars in oncology. 1991 Review GET IT
Times cited: 19
Twice daily thoracic irradiation for limited small cell lung cancer. International journal of radiation oncology, biology, physics. 1991 Academic Article GET IT
Times cited: 11
Limited small-cell lung cancer: do favorable short-term results predict ultimate outcome?. American journal of clinical oncology. 1991 Academic Article GET IT
Times cited: 4
Prostatic cancer: where do we go from here?. Current opinion in oncology. 1991 Review GET IT
Times cited: 1
Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer. 1991 Academic Article GET IT
Times cited: 129
Limited small cell lung cancer: prognostic significance of a complete response to the induction phase of chemotherapy followed by thoracic irradiation. Radiology. 1991 Academic Article GET IT
Times cited: 2
Phase II trial of Didemnin B in patients with advanced renal cell carcinoma. Investigational new drugs. 1990 Academic Article GET IT
Times cited: 14
Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1990 Academic Article GET IT
Times cited: 63
Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1990 Academic Article GET IT
Times cited: 253
Can we combine available data to evaluate the effects of neoadjuvant chemotherapy for invasive bladder cancer?. Seminars in oncology. 1990 Academic Article GET IT
Times cited: 9
Chemotherapy for invasive bladder cancer: introduction. Seminars in oncology. 1990 Academic Article GET IT
Chemotherapy for invasive bladder cancer: neoadjuvant versus adjuvant. Seminars in oncology. 1990 Review GET IT
Times cited: 40
Neoadjuvant chemotherapy for invasive bladder cancer: future directions. Seminars in oncology. 1990 Review GET IT
Times cited: 4
Surgery of invasive bladder cancer: is pathologic staging necessary?. Seminars in oncology. 1990 Review GET IT
Times cited: 18
Neoadjuvant chemotherapy for bladder cancer: the MSKCC experience. Seminars in urology. 1990 Academic Article GET IT
Times cited: 7
Transrectal sonography for serial evaluation of prostatic malignancy. Urology. 1990 Academic Article GET IT
Times cited: 3
Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology. 1990 Academic Article GET IT
Times cited: 147
Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors. Cancer. 1990 Academic Article GET IT
Times cited: 31
Predicting biologic potential in prostate cancer. Current opinion in oncology. 1990 Review GET IT
Times cited: 1
Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency. 1990 GET IT
Times cited: 37
Chemotherapy for invasive bladder tumors. Progress in clinical and biological research. 1990 Review GET IT
Times cited: 8
M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) and bladder preservation. Progress in clinical and biological research. 1990 Academic Article GET IT
Times cited: 21
The prognostic value of the pT-category after combination chemotherapy for patients with invasive bladder cancer who underwent cystectomy. EORTC-GU group. Progress in clinical and biological research. 1990 Academic Article GET IT
Times cited: 19
The staging of M+ disease. Progress in clinical and biological research. 1990 Conference Paper GET IT
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer. 1989 Academic Article GET IT
Times cited: 643
Palliative hemiskeletal irradiation for widespread metastatic prostate cancer: a comparison of single dose and fractionated regimens. International journal of radiation oncology, biology, physics. 1989 Academic Article GET IT
Times cited: 59
Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen. British journal of urology. 1989 Academic Article GET IT
Times cited: 102
Should single agents be standard therapy for urothelial tract tumors?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1989 Academic Article GET IT
Times cited: 18
Phase II trial of trimetrexate in patients with advanced renal cell carcinoma. Clinical Community Oncology Program. European journal of cancer & clinical oncology. 1989 Academic Article GET IT
Times cited: 7
Is chemotherapy a new form of radical treatment in infiltrating tumor localized to the bladder?. Progress in clinical and biological research. 1989 Academic Article GET IT
Times cited: 6
Neoadjuvant chemotherapy of invasive bladder cancer. The prognostic value of local tumor response. Progress in clinical and biological research. 1989 Academic Article GET IT
Times cited: 5
Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. The Journal of clinical investigation. 1988 Academic Article GET IT
Times cited: 199
A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1988 Academic Article GET IT
Times cited: 216
Recombinant human granulocyte colony stimulating factors: therapeutic application in the prevention of chemotherapy-induced neutropenia. Behring Institute Mitteilungen. 1988 Academic Article GET IT
Times cited: 2
Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. The New England journal of medicine. 1988 Academic Article GET IT
Times cited: 820
Serial transabdominal sonography of bladder cancer. AJR. American journal of roentgenology. 1988 Academic Article GET IT
Times cited: 10
Randomized trial of combined modality therapy with and without thymosin fraction V in the treatment of small cell lung cancer. Cancer research. 1988 Academic Article GET IT
Times cited: 20
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. The Journal of urology. 1988 Academic Article GET IT
Times cited: 442
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. The Journal of urology. 1988 Academic Article GET IT
Times cited: 186
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumors. The Journal of urology. 1988 Academic Article GET IT
Times cited: 40
Chemotherapeutic management of invasive bladder carcinoma. European urology. 1988 Academic Article GET IT
Times cited: 2
Chemotherapy for advanced urothelial tract tumors: the M-VAC regimen. Progress in clinical and biological research. 1988 Academic Article GET IT
Times cited: 5
Day hospital as an alternative to inpatient care for cancer patients: a random assignment trial. Journal of clinical epidemiology. 1988 Academic Article GET IT
Times cited: 51
M-VAC: methotrexate (MTX), vinblastine (VLB), adriamycin (ADM), and cisplatin (DDP) for metastatic and node positive carcinoma of the urothelium. Progress in clinical and biological research. 1988 Academic Article GET IT
Times cited: 2
Neo-adjuvant M-VAC chemotherapy trials in transitional cell carcinoma: perspectives for first line chemotherapy. Progress in clinical and biological research. 1988 Review GET IT
Preliminary results of combination chemotherapy and sequential accelerated fractionation radiation therapy in limited-stage small cell carcinoma of the lung. Evaluation of measures for reduction of toxicity and effect on complete response rate. Antibiotics and chemotherapy. 1988 Academic Article GET IT
Times cited: 1
Gallium nitrate in prostatic cancer: evaluation of antitumor activity and effects on bone turnover. Cancer treatment reports. 1987 Academic Article GET IT
Times cited: 31
Current status of chemotherapy for urothelial tract tumors. Oncology (Williston Park, N.Y.). 1987 Review GET IT
Times cited: 10
Advances in the treatment of urothelial tract tumors. The Urologic clinics of North America. 1987 Review GET IT
Times cited: 14
Sonography in evaluation of carcinoma of bladder. Urology. 1987 Academic Article GET IT
Times cited: 16
Bone metastases: pathogenesis, treatment, and rationale for use of resorption inhibitors. The American journal of medicine. 1987 Review GET IT
Times cited: 81
Surgical treatment of spinal cord compression in kidney cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1986 Academic Article GET IT
Times cited: 80
Phase II trial of N-methylformamide for advanced renal cell carcinoma. Cancer treatment reports. 1986 Academic Article GET IT
Times cited: 16
Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease. Cancer chemotherapy and pharmacology. 1986 Academic Article GET IT
Times cited: 17
Phase II trial of 10 deaza-aminopterin in patients with bladder cancer. Investigational new drugs. 1986 Academic Article GET IT
Times cited: 4
Increased survival with high-dose multifield radiotherapy and intensive chemotherapy in limited small cell carcinoma of the lung. Cancer. 1985 Academic Article GET IT
Times cited: 33
Chemotherapy of urologic malignancies. Seminars in urology. 1985 Review GET IT
Times cited: 35
Vinblastine and methotrexate for advanced bladder cancer. The Journal of urology. 1985 Academic Article GET IT
Times cited: 16
Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. The Journal of urology. 1985 Academic Article GET IT
Times cited: 558
Methylglyoxal-bis(guanylhydrazone) in hormone-resistant adenocarcinoma of the prostate. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1985 Academic Article GET IT
Times cited: 15
Controversies in treatment of small cell carcinoma of the lung. Cancer investigation. 1985 Review GET IT
Times cited: 10
Experimental studies and phase II trial of bisantrene in advanced urothelial malignancies. Cancer investigation. 1985 Academic Article GET IT
Times cited: 3
Phase II trial of elliptinium in advanced renal cell carcinoma and carcinoma of the breast. Anticancer research. 1985 Academic Article GET IT
Times cited: 13
Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma. Cancer chemotherapy and pharmacology. 1985 Academic Article GET IT
Times cited: 15
Estrogen, progesterone, and androgen-binding sites in renal cell carcinoma. Observations obtained in Phase II trial of flutamide. Cancer. 1984 Academic Article GET IT
Times cited: 20
Phase II trial of doxorubicin in bidimensionally measurable prostatic adenocarcinoma. The Journal of urology. 1984 Academic Article GET IT
Times cited: 40
Phase II trial of mitoguazone in patients with relapsed small cell carcinoma of the lung. Cancer treatment reports. 1984 Academic Article GET IT
Times cited: 4
Phase II trial of 10-deazaaminopterin for advanced hypernephroma. Anticancer research. 1984 Academic Article GET IT
Times cited: 6
Phase-II trial of 1,2-diaminocyclohexane (4-carboxyphthalato) platinum (II) (DACCP) in non-small cell lung cancer. Cancer chemotherapy and pharmacology. 1984 Academic Article GET IT
Times cited: 10
Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer research. 1983 Academic Article GET IT
Times cited: 233
Impact of symptomatic interval on prognosis of patients with stage III testicular cancer. Urology. 1983 Academic Article GET IT
Times cited: 19
Phase I clinical trial and pharmacokinetics of 4'-carboxyphthalato(1,2-diaminocyclohexane)platinum(II). Cancer research. 1982 Academic Article GET IT
Times cited: 30
Phase II trial of bisantrene for advanced hypernephroma. Cancer treatment reports. 1982 Academic Article GET IT
Times cited: 8
Genetic control of immune response toward the loop region of lysozyme. Journal of immunology (Baltimore, Md. : 1950). 1973 Academic Article GET IT
Times cited: 13

more ...

less ...

Background

education and training

M.D., New York University School of Medicine 1976
B.S., Bates College 1972

Contact

full name

Howard Scher

VIVO Weill Cornell Medical College

Howard Scher Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name